Phase II Study of Combined Modality Treatment in Primary Testicular Non-Hodgkin's Lymphoma

Lymphoma, B Cell Clinical Trial

Official title:
A Phase II Study of CHOP + Rituximab, With Intrathecal Methotrexate Followed by Radiotherapy in Patients With Primary Testicular Non-Hodgkin's Lymphoma

Status Completed

Clinical Trial Summary

The primary objective assess the clinical activity of combination doxorubicin-containing chemotherapy plus monoclonal antibody anti-CD20 (Rituximab) plus intrathecal prophylactic chemotherapy and loco-regional radiotherapy in primary localised testicular DLCL and to assess the toxicity of this therapeutic strategy

Clinical Trial Description

n/a

Study Design

Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT00210379
Study type	Interventional
Source	International Extranodal Lymphoma Study Group (IELSG)
Contact
Status	Completed
Phase	Phase 2
Start date	November 2000
Completion date	March 2007

View Details

See also
Status	Clinical Trial	Phase
Terminated	`NCT00523939` - DepoCyt for Active Lymphomatous or Leukemic Meningitis	Phase 2
Completed	`NCT02679196` - The Safety, Pharmacokinetic and Pharmacodynamic Effect of KA2237 (PI3 Kinase p110β/δ Inhibitor) In B Cell Lymphoma	Phase 1
Completed	`NCT00210314` - Phase II Trial of Combined Modality Treatment in Primary Central Nervous System Lymphoma	Phase 2
Not yet recruiting	`NCT02992834` - Anti-CD19:TCRζ Chimeric Antigen Receptor-T Cells in the Treatment for CD19+ B Cell Lymphoma	Phase 4
Withdrawn	`NCT00210340` - A Phase I Study of Intrathecal Rituximab in Patients With Lymphomatous Meningitis	Phase 1